Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT00422162 Completed - Clinical trials for Major Depressive Disorder

A Study Evaluating Duloxetine in Patients Hospitalized for Severe Depression

Start date: February 2007
Phase: Phase 4
Study type: Interventional

An eight-week, randomized, double blind, two parallel groups, study to assess clinical response of duloxetine 60 milligrams (mg) and 120 mg per day in patients hospitalized for severe depression.

NCT ID: NCT00421954 Completed - Bipolar Disorder Clinical Trials

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

Start date: May 2006
Phase: Phase 3
Study type: Interventional

This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder. Eligible adolescents will receive Geodon® for 7 weeks and stay at the NYSPI Children's Day Unit (CDU) during the day. If clinically appropriate, they may also stay at the New York State Psychiatric Institute (NYSPI) Schizophrenia Research Unit (SRU) inpatient facility.

NCT ID: NCT00421369 Completed - Clinical trials for Major Depressive Disorder

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Start date: September 2007
Phase: N/A
Study type: Interventional

In this project we aim to further refine indications for the use of the thyroid hormone - T3 for patients suffering from depression. We aim to identify a sub-group of patients who are more likely to respond to T3 and establish the time in the treatment course when T3 should be added. The results of this project could have significant, direct clinical implications.

NCT ID: NCT00420641 Completed - Depressive Disorder Clinical Trials

MDD POC Study GSK372475 Subjects Depressive Disease

Start date: December 19, 2006
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.

NCT ID: NCT00420004 Completed - Clinical trials for Major Depressive Disorder

A Study for Participants With Major Depression

Start date: December 2006
Phase: Phase 2
Study type: Interventional

This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.

NCT ID: NCT00419471 Completed - Coronary Disease Clinical Trials

Escitalopram in Depressive Patients With Acute Coronary Artery Syndrome

Start date: May 2007
Phase: Phase 4
Study type: Interventional

This study aimed to evaluate the efficacy and safety of escitalopram in the treatment of depressive patients with acute coronary artery syndrome (CAS).

NCT ID: NCT00419003 Completed - Major Depression Clinical Trials

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

Start date: December 2006
Phase: Phase 4
Study type: Interventional

This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder. This study will also examine the effectiveness of an FDA approved drug called lamotrigine in decreasing the potential side effects associated with ketamine.

NCT ID: NCT00415142 Completed - Depressive Disorder Clinical Trials

An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder

Start date: December 2006
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients with major depressive disorder.To evaluate plasma concentrations of saredutant and SR49596 (inactive metabolite).To evaluate safety and tolerability of 24 weeks of additional treatment in patients completing the initial 8-week treatment period.

NCT ID: NCT00414323 Completed - Clinical trials for Major Depressive Disorder

Evaluation of the Effects of Duloxetine on Norepinephrine

Start date: November 2006
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate how taking duloxetine 60mg every day affects the transfer of two normal body chemicals, 3,4-dihydroxyphenylglycol (DHPG) and norepinephrine (NE), across cells in blood and cerebrospinal fluid.

NCT ID: NCT00413023 Completed - Clinical trials for Depressive Disorder, Major

Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)

Start date: June 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety and tolerability of GW679769 patients with Major depressive Disorder (MDD).